Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1928 studies found for:    new vaccines
Show Display Options
Rank Status Study
1 Completed Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)
Conditions: HDL;   Drug Safety
Intervention: Biological: ATH03
2 Active, not recruiting MenPF-1 - A New Vaccine Against Meningococcal Disease
Condition: Serogroup B Meningococcal Disease
Intervention: Biological: MenPF-1.
3 Recruiting Complement 2: Blood Donations to Develop Vaccines Against Infectious Diseases
Condition: Complement Mediated Bacterial Killing in Healthy Adults
Intervention:
4 Completed RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: PanAd3-RSV given intra-nasally (high dose);   Biological: MVA-RSV given by intra-muscular injection (high dose);   Biological: PanAd3-RSV given by intra-muscular injection (high dose);   Biological: PanAd3-RSV given intranasally (low dose);   Biological: MVA-RSV given by intra-muscular injection (low dose);   Biological: PanAd3-RSV given by intra-muscular injection (low dose)
5 Completed An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84
Condition: Clostridium Difficile Infection
Intervention: Biological: IC84
6 Recruiting Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis
Conditions: Pneumococcal Infection;   ANCA-associated Vasculitis
Intervention:
7 Recruiting Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis
Condition: Lyme Borreliosis, Nervous System
Interventions: Biological: VLA15 with Alum;   Biological: VLA15 without Alum
8 Completed Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Condition: Melanoma
Intervention: Biological: Immunotherapeutic GSK2302025A, different formulations
9 Completed Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47
Condition: Pneumococcal Infections
Intervention: Biological: IC47
10 Recruiting Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability
Condition: Zika Virus
Interventions: Biological: MV-ZIKA;   Other: Placebo
11 Withdrawn Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients
Condition: Parkinson's Disease
Interventions: Biological: AFFITOPE® PD01A + Adjuvant;   Biological: Adjuvant without active component
12 Completed
Has Results
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
Condition: Meningococcal Vaccine
Interventions: Biological: rLP2086;   Biological: Havrix (HAV);   Biological: Saline
13 Completed A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
Condition: MENINGOCOCCAL INFECTION
Interventions: Biological: Bivalent rLP2086 Vaccine;   Biological: Licensed pediatric hepatits A vaccine;   Other: Normal Saline
14 Completed
Has Results
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
Condition: Healthy
Interventions: Biological: rLP2086;   Other: Placebo
15 Completed Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects
Condition: Infections, Meningococcal
Intervention: Biological: Meningococcal vaccine GSK134612
16 Completed
Has Results
Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
Condition: Smallpox
Interventions: Biological: Vaccinia virus: ACAM2000 smallpox vaccine;   Biological: vaccinia virus (calf lymph): Dryvax
17 Terminated Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
Condition: Smallpox
Interventions: Biological: ACAM1000;   Biological: vaccinia virus (calf lymph) smallpox vaccine: Dryvax
18 Completed A Study of the Safety and Effectiveness of Two New Malaria Vaccines
Condition: Malaria
Interventions: Biological: AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine;   Biological: AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge
19 Completed Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease
Condition: Hormonal Refractory Prostate Cancer
Intervention: Biological: CV9103
20 Completed T−Cell Turnover Following Vaccination With MVA85A
Condition: Tuberculosis
Interventions: Biological: MVA85A;   Other: Deuterated glucose infusion

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.